MedTrace Logo

Ceftobiprole's Cerebrospinal Fluid Penetration in Patients With External Ventricular Derivation (CEFTO-EVD)

NCT04178629 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 15

Last updated 2019-11-26

No results posted yet for this study

Summary

The Cerebrospinal fluid penetration of ceftobiprole has been studied in an animal model of meningitidis. Ceftobiprole is bactericidal, well tolerated and it has anti-biofilm activity. Altogether, these pharmacodynamics and pharmacokinetic properties of ceftobiprole are suitable for its use in case of External Ventricular Derivation(EVD)-related ventriculitis. Nowadays there are no human studies on the penetration and efficacy of ceftobiprole in the CSF. The study aims to evaluate characteristics of the CSF penetration of Ceftobiprole after intravenous administration in patients with EVD, that need for a concomitant infection this therapy (prescribed by an Infectious Diseases doctor).

Conditions

  • Pharmacokinetics
  • Cerebral Ventriculitis
  • Cephalosporins
  • Cerebrospinal Fluid

Sponsors & Collaborators

  • University of Turin, Italy

    collaborator OTHER

  • University of Pisa

    collaborator OTHER

  • Università degli Studi di Brescia

    collaborator OTHER

  • Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

    lead OTHER

Principal Investigators

  • Simone Piva · Università degli Studi di Brescia

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-02
Primary Completion
2020-11-01
Completion
2020-11-01

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04178629 on ClinicalTrials.gov